Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel

MT newswire2026/10/06 11:49

07:49 AM EDT, 10/06/2026 (MT Newswires) -- Kamada (KMDA) has launched two additional biosimilars in Israel, expanding its portfolio to four products, the company said Tuesday. The two new products are Ustekinumab-Kamada, a Stelara biosimilar, and Enoxaparin-Kamada, a Clexane biosimilar, the company said. The launches follow two earlier biosimilars introduced in Israel, with Kamada expecting at least two more products to become commercially available next year. Kamada expects biosimilar sales to rise from $4 million in 2026 to $10 million in 2028, with at least 12 marketed products generating $20 million to $25 million in annual revenue by 2030, the company said. Shares of Kamada were up 1.6% in recent Tuesday premarket activity.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.